G E U A N Y 格 远 律 师 事 务 所 ——— Law Firm 关于山西锦波生物医药股份有限公司 2025 年第三次临时股东会的 法律意见书 山西格远 律师事 山西格远律师事务所 关于山西锦波生物医药股份有限公司 2025年第三次临时股东会的 法律意见书 致:山西锦波生物医药股份有限公司 根据《中华人民共和国证券法(2019年修订)》(以下简称"《证券法》")《中 华人民共和国公司法(2023年修正)》(以下简称"《公司法》")《北京证券交易 所上市公司持续监管办法》《上市公司信息披露管理办法》等法律、法规和其他 有关规范性文件的要求,山西格远律师事务所(以下简称"本所")接受山西锦 波生物医药股份有限公司(以下简称"锦波生物"或"公司")的委托,指派律 师参加公司 2025 年第三次临时股东会(以下简称"本次股东会"或"本次会议")。 为出具本《法律意见书》,本所声明如下: 1、本所律师仅对本次股东会的召集程序、召开程序、出席会议人员资格、 召集人资格、表决程序、表决结果及会议决议发表法律意见,并不对本次股东会 所审议的议案、议案所涉及的数字及内容发表意见。 2、本所及经办律师依据《证券法》《 ...

证券之星消息，8月29日医疗美容板块较上一交易日上涨0.59%，锦波生物领涨。当日上证指数报收于 3857.93，上涨0.37%。深证成指报收于12696.15，上涨0.99%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 832982 | 锦波生物 | 312.48 | 4.41% | 1.42万 | 4.42 Z | | 300896 | 爱美客 | 193.98 | 1.90% | 4.87万 | 9.46 Z | | 688363 | 华熙生物 | 57.20 | -1.00% | 6.42万 | 3.69 Z | | 000615 | *ST美谷 | 3.13 | -2.49% | 12.04万 | 3799.03万 | 从资金流向上来看，当日医疗美容板块主力资金净流入6073.29万元，游资资金净流出3892.41万元，散户 资金净流出2180.88万元。医疗美容板块个股资金流向见下表： | 代码 | | | 名称 | | | | | --- | -- ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][7] Core Views - The company reported a revenue of 859 million yuan for the first half of 2025, representing a year-on-year growth of 42.43%, and a net profit attributable to shareholders of 392 million yuan, up 26.65% year-on-year [2][4] - The second quarter of 2025 saw a revenue of 492 million yuan, a year-on-year increase of 30.44%, and a net profit of 224 million yuan, which is a 7.36% increase year-on-year [4] - The company is actively expanding its overseas business, having achieved significant progress in the global layout of its recombinant human collagen medical devices, including obtaining medical device registration in Thailand [4] Summary by Relevant Sections Financial Performance - For the first half of 2025, the company achieved a gross margin of 90.68%, a decrease of 0.9 percentage points compared to the same period last year [4] - Medical device revenue reached 708 million yuan, growing 33.41% year-on-year, with a gross margin of 95.04%, an increase of 0.61 percentage points [4] - Functional skincare products generated 121 million yuan in revenue, a significant increase of 152.39% year-on-year, with a gross margin of 70.78%, up 6.02 percentage points [4] Future Earnings Forecast - The company is expected to have earnings per share of 8.93 yuan and 12.39 yuan for 2025 and 2026, respectively, with corresponding price-to-earnings ratios of 34 times and 24 times [4][6]

（原标题：21家北交所公司推出分红方案） 半年报分红季来临，共有21家北交所公司公布了分配方案，分配方案中，涉及派现的有21家。 证券时报•数据宝统计，公布现金分红方案公司中，锦波生物分红最慷慨，公司8月11日公布10派10元 （含税）的分配方案，以此测算，派现金额达1.15亿元；其次是天工股份、广信科技等，派现金额为 6556.00万元、5999.97万元。以每10股派现金额统计，每10股派现金额超过5元的共有3家，派现金额居 前的有锦波生物、酉立智能、广信科技等，每10股派现金额分别为10元、10元、6.56元。按派现金额占 净利润比例，派现比例居前的有许昌智能、鹿得医疗、联迪信息等，派现率分别为290.92%、 175.68%、117.02%。（数据宝） | 代码 | 简称 | 预案公布日 | 每10股 派现 | 每10股 送转 | 预案公布 | 预案公布 | 派现金额 | 派现 占净利润 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 次日涨跌 | 后涨跌 | | | | | | | （元） | （股） | （ ...

Group 1 - The medical beauty sector increased by 0.6% on August 28, with Huaxi Biological leading the gains [1] - The Shanghai Composite Index closed at 3843.6, up 1.14%, while the Shenzhen Component Index closed at 12571.37, up 2.25% [1] - The closing prices and performance of key stocks in the medical beauty sector include: - Huaxi Biological: 57.78, up 1.60%, with a trading volume of 82,100 shares and a turnover of 471 million yuan - Aimeike: 190.36, up 0.17%, with a trading volume of 49,700 shares and a turnover of 940.1 million yuan - Jinbo Biological: 299.27, down 1.81%, with a trading volume of 9,644 shares and a turnover of 289 million yuan - *ST Meigu: 3.21, down 3.60%, with a trading volume of 195,800 shares and a turnover of 62.64 million yuan [1] Group 2 - The medical beauty sector experienced a net outflow of 122 million yuan from main funds, while retail funds saw a net inflow of 66.68 million yuan [1] - The fund flow for key stocks shows: - *ST Meigu: net outflow of 5.87 million yuan, down 9.37% - Huaxi Biological: net outflow of 27.85 million yuan, down 5.92% - Aimeike: net outflow of 88.21 million yuan, down 9.39% [2]

截至8月27日，北交所融资融券余额合计74.73亿元，较前一交易日增加9349.21万元，其中，融资余额 74.72亿元，较前一交易日增加9336.67万元，为连续3个交易日增加；融券余额为59.39万元，较前一交 易日增加12.54万元。 证券时报·数据宝统计显示，截至8月27日，北交所股票中，融资余额居前的为锦波生物、曙光数创、艾 融软件，最新融资余额分别为3.32亿元、2.29亿元、1.79亿元，从最新融资余额占流通市值比例看，算 术平均值为1.33%，最新融资余额占流通市值比例居前的有民士达、万源通、德众汽车等，占比分别为 4.57%、4.02%、3.79%。 北交所股票中，8月27日共有152只股获融资净买入，净买入金额在500万元以上的有14只，曙光数创融 资净买入额居首，当日净买入1627.02万元，其次是聚星科技、恒拓开源，融资净买入金额分别为828.46 万元、793.52万元，融资净买入金额居前的还有贝特瑞、邦德股份、能之光等。融资净卖出金额居前的 股票为鼎智科技、五新隧装、开特股份等，融资净卖出金额分别为1133.11万元、829.48万元、534.55万 元。 分行业统计，获融资净买入 ...

Core Insights - The "specialized and innovative" small giants are accelerating, with hidden champions in niche industries increasing their market share [1] - As of August 27, 2025, 192 out of 273 listed companies on the North Exchange have released their semi-annual reports, with a profitability rate of approximately 87.5% [1] - The majority of profitable companies are concentrated in the machinery equipment (24%), automotive (11%), electric power equipment (10%), and basic chemicals (10%) sectors [1] Revenue Performance - Nine companies on the North Exchange achieved revenue exceeding 1 billion yuan in the first half of 2025, with 150 companies surpassing 100 million yuan [3] - The top three companies by revenue are: - Innoway: 3.55 billion yuan - Tongli Co., Ltd.: 3.17 billion yuan - Yingtai Biotechnology: 2.97 billion yuan [4] Profitability - Three companies reported a net profit exceeding 100 million yuan, while 22 companies had a net profit over 50 million yuan [5] - Jinbo Biological, a leading company in the medical beauty and functional skincare sector, reported a net profit of 392 million yuan, a year-on-year increase of 26.65% [6][7] Growth Rates - Among the 22 companies that doubled their profits, Shibi Bai reported a staggering net profit growth of nearly 60 times, achieving a net profit of approximately 29.23 million yuan [9] - The company attributed its success to increased sales driven by government subsidies and improved internal management, leading to enhanced product quality and profit margins [9] Industry Trends - The machinery equipment sector has a high representation among the profitable companies, with Tongli Co., Ltd. being one of the notable firms with a market capitalization of approximately 10.31 billion yuan [9] - Tongli Co., Ltd. is actively advancing in the fields of new energy and autonomous driving, having delivered seven electric non-road dump trucks for a project in Mongolia [10]

中信证券股份有限公司 关于山西锦波生物医药股份有限公司 根据《证券发行上市保荐业务管理办法》《北京证券交易所股票上市规则》 等有关法律法规、规范性文件等的规定，中信证券股份有限公司（以下简称"中 信证券"或"保荐机构"）山西锦波生物医药股份有限公司（以下简称"锦波生 物""上市公司""公司"）的保荐机构，负责锦波生物的持续督导工作，并出具 2025 年半年度持续督导跟踪报告。 | 序号 | 工作要求 | 完成或督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导业务管理制度，制 | 中信证券已建立健全并有效执 | | | 定持续督导工作计划和实施方案，就持续督导工 | 行持续督导工作制度，并已根据 | | | 作的主要内容、重点、实施方式、步骤等做出完 | 上市公司的具体情况制定了相 | | | 整、有效的安排。 | 应的持续督导工作计划和安排。 | | | | 本持续督导期间，保荐机构查阅 | | | | 了上市公司《公司章程》《承诺 | | | | 管理制度》《内部审计制度》《关 | | | 督导上市公司建立健全并有效执行公司治理制 | 联交易管理制度》等公司内部制 ...

Market Overview - The medical beauty sector experienced a decline of 3.11% on August 27, with Aimeike leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Individual Stock Performance - Aimeike (300896) closed at 190.03, down 3.88%, with a trading volume of 62,200 shares and a transaction value of 1.207 billion yuan [1] - Huaxi Biological (688363) closed at 56.87, down 2.25%, with a trading volume of 99,400 shares and a transaction value of 580 million yuan [1] - Jinbo Biological (832982) closed at 304.80, down 3.24%, with a trading volume of 10,300 shares and a transaction value of 319 million yuan [1] - ST Meigu (000615) remained unchanged at 3.33, with a trading volume of 142,300 shares and a transaction value of 47.7013 million yuan [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 199 million yuan from main funds, while retail investors contributed a net inflow of 153 million yuan [1] - Aimeike experienced a net outflow of 143 million yuan from main funds, with retail investors contributing a net inflow of 98.8281 million yuan [2] - Huaxi Biological had a net outflow of 57.973 million yuan from main funds, but a net inflow of 53.4443 million yuan from retail investors [2]

证券代码：832982 证券简称：锦波生物 公告编号：2025-142 山西锦波生物医药股份有限公司 股票解除限售公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、本次股票解除限售数量总额为 1,559,969 股，占公司总股本 1.356%，可交 易时间为 2025 年 8 月 29 日。 注：如公司近期办理过新增股份登记的，公司总股本以新增股份登记后的总股本为准。 四、其它情况 本次解除限售的股东如属于《北京证券交易所股票上市规则》《北京证券交 易所上市公司持续监管指引第 8 号——股份减持》等规定的减持预披露主体，若 后续减持股份，将在减持前及时履行信息披露义务。 二、本次股票解除限售的明细情况及原因 单位：股 | 序号 | 股东姓 名或名 | 是否为 控股股 东、实际 | 董事、监事、 | 本次解 | 本次解除限 | 本次解除 限售股数 | 尚未解除 限售的股 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | ...